Liraglutide Slows Bile Duct Cancer Progression by Blocking Cell Migration and Key Signaling Pathways
Liraglutide suppressed cholangiocarcinoma cell migration and reduced tumor growth in mice by inhibiting epithelial-mesenchymal transition and Akt/STAT3 signaling, while GLP-1R expression was linked to poorer tumor grade.
Quick Facts
What This Study Found
Liraglutide suppressed CCA cell migration and reduced xenograft tumor volumes by inhibiting EMT and Akt/STAT3 phosphorylation, despite GLP-1R expression being associated with poorer histological grade.
Key Numbers
GLP-1R expression significantly associated with poor histological grading (P = 0.027). Two iCCA cell lines tested (KKU-055 and KKU-213A).
How They Did This
Immunohistochemistry of GLP-1R in human CCA tissues, in vitro proliferation and migration assays in CCA cell lines (KKU-055, KKU-213A) with exendin-4 and liraglutide, and in vivo xenograft mouse tumor models.
Why This Research Matters
With millions of diabetic patients now on GLP-1 agonists, understanding their effects on cancer is critical. This study suggests liraglutide may have anti-tumor effects on bile duct cancer, a notoriously difficult malignancy with few treatment options.
The Bigger Picture
The relationship between GLP-1 agonists and cancer is complex and controversial. This study adds evidence that liraglutide may actually slow certain cancers, which could influence treatment decisions for diabetic patients with CCA risk factors.
What This Study Doesn't Tell Us
Cell line studies may not represent all CCA subtypes; xenograft mice are immunocompromised (may not reflect immune-competent tumor responses); limited sample sizes; only liraglutide and exendin-4 tested; human clinical validation needed; GLP-1R as both risk marker and treatment target creates paradox.
Questions This Raises
- ?Does the paradox of GLP-1R marking poor grade but liraglutide being protective suggest receptor-independent effects?
- ?Would liraglutide benefit diabetic patients at risk for cholangiocarcinoma?
- ?Does GLP-1R downregulation limit long-term anti-tumor efficacy?
Trust & Context
- Key Stat:
- Tumor volume reduced liraglutide significantly reduced CCA xenograft tumor size (P=0.046)
- Evidence Grade:
- Preliminary preclinical evidence from cell lines and mouse xenografts. Interesting and novel but requires human clinical investigation.
- Study Age:
- Published in 2024, contributing to the evolving understanding of GLP-1 agonists' effects on cancer biology.
- Original Title:
- Liraglutide exhibits potential anti-tumor effects on the progression of intrahepatic cholangiocarcinoma, in vitro and in vivo.
- Published In:
- Scientific reports, 14(1), 13726 (2024)
- Authors:
- Trakoonsenathong, Ronnakrit, Kunprom, Waritta, Aphivatanasiri, Chaiwat, Yueangchantuek, Padcharee, Pimkeeree, Paslada, Sorin, Supannika, Khawkhiaw, Kullanat, Chiu, Ching-Feng, Okada, Seiji, Wongkham, Sopit, Saengboonmee, Charupong
- Database ID:
- RPEP-09400
Evidence Hierarchy
Frequently Asked Questions
Could GLP-1 drugs like liraglutide help fight bile duct cancer?
This preclinical study suggests yes — liraglutide stopped cancer cells from migrating and reduced tumor size in mice. However, the finding that the drug's receptor is also linked to worse cancer grade creates a paradox that needs human study.
Should cancer patients worry about taking GLP-1 medications?
This study actually suggests the opposite for bile duct cancer — liraglutide appeared to slow cancer progression. However, the relationship between GLP-1 drugs and different cancers varies, and patients should discuss concerns with their oncologist.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09400APA
Trakoonsenathong, Ronnakrit; Kunprom, Waritta; Aphivatanasiri, Chaiwat; Yueangchantuek, Padcharee; Pimkeeree, Paslada; Sorin, Supannika; Khawkhiaw, Kullanat; Chiu, Ching-Feng; Okada, Seiji; Wongkham, Sopit; Saengboonmee, Charupong. (2024). Liraglutide exhibits potential anti-tumor effects on the progression of intrahepatic cholangiocarcinoma, in vitro and in vivo.. Scientific reports, 14(1), 13726. https://doi.org/10.1038/s41598-024-64774-2
MLA
Trakoonsenathong, Ronnakrit, et al. "Liraglutide exhibits potential anti-tumor effects on the progression of intrahepatic cholangiocarcinoma, in vitro and in vivo.." Scientific reports, 2024. https://doi.org/10.1038/s41598-024-64774-2
RethinkPeptides
RethinkPeptides Research Database. "Liraglutide exhibits potential anti-tumor effects on the pro..." RPEP-09400. Retrieved from https://rethinkpeptides.com/research/trakoonsenathong-2024-liraglutide-exhibits-potential-antitumor
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.